

CIPROVET®

tablets

INSTRUCTIONS

on veterinary use of the drug CIPROVET® tablets

Approved by the Deputy Head of Rosselkhoznadzor Vlasov N.A.

(Developer organization: NVT Agrovetzaschita LLC, Russia, 129329, Moscow, Igarsky passage, 4, h. 2)

Registration certificate number: in Russia 77-3-1.15-4397 № VDR-3-11.9/02505 dated 25.01.2019

I. General information

Name of the drug for veterinary use:

trade name – CIPROVET® tablets (CIPROVET® tablets)

the international nonproprietary name is ciprofloxacin.

Dosage form: tablets for oral use.

CIPROVET® tablets are produced in two dosages – “CIPROVET® tablets for dogs” and “CIPROVET® tablets for cats and dogs of small breeds”, containing 50 mg and 15 mg hydrochloride as the active ingredient in 1 tablet of ciprofloxacin, respectively, as well as excipients: lactose, lactulose, calcium stearate and polyvinylpyrrolidone.

In appearance, the drug is a biconvex tablets weighing 0.2 g, coated from white to gray (tablets for dogs) or yellow (tablets for cats and dogs of small breeds).

Expiration date of CIPROVET® tablets under the conditions of storage in the manufacturer's closed packaging – 4 years from the date of production. It is forbidden to use the drug after the expiration date.

The drug is produced packaged in 10 tablets in blisters, packed in 1, 2 or 3 pieces in cardboard packs with instructions for use.

CIPROVET® tablets are stored in the manufacturer's closed packaging, in a place protected from direct sunlight, separately from food and feed, at a temperature from 0 °C to 25 °C.

CIPROVET® tablets are stored out of the reach of children.

Unused drug is disposed of in accordance with the requirements of the legislation.

It is released without a prescription from a veterinarian.

II. Pharmacological properties

CIPROVET® tablets belong to the group of antibacterial agents.

Ciprofloxacin, which is part of the drug – a compound of the fluoroquinolone group, has

a wide spectrum of antibacterial action, is active against gram-positive and gram-negative bacteria, including *Echerichia coli*, *Salmonella* spp., *Shigella* spp., *Klebsiella* spp., *Enterobacter* spp., *Proteus* spp., *Yersinia* spp., *Haemophilus* spp., *Pseudomonas aeruginosa*, *Pasteurella multocida*, *Plesiomonas shigelloides*, *Campylobacter jejuni*, *Brucella* spp., *Chlamydia trachomatis*, *Listeria monocytogenes*, *Mycobacterium* spp., *Corynebacterium diphtheriae*, *Staphylococcus* spp., *Streptococcus* spp.

The mechanism of action of ciprofloxacin is based on blocking the DNA gyrase enzyme, which affects the replication of the DNA helix in the bacterial nucleus, which leads to disruption of protein synthesis and rapid death of the bacterial cell. Bactericidal activity is expressed on gram-negative microorganisms during dormancy and division (because it affects not only DNA gyrase, but also causes lysis of the cell wall), on gram-positive microorganisms - only during division.

Lactulose, as a prebiotic substance, enhances the growth of beneficial bacteria such as *Bifidobacteria* and *Lactobacilli*, and contributes to the suppression of the growth of potentially pathogenic bacteria such as *Clostridium* and *Escherichia coli*. It stimulates intestinal peristalsis, improves the absorption of phosphates and Ca^{2+} salts, promotes the excretion of ammonium ions. These processes lead to the normalization of the microflora in the intestine, reducing the formation of ammonia.

After oral administration, ciprofloxacin is easily absorbed in the gastrointestinal tract (mainly in the duodenum and colon), distributed in organs and tissues of the body (excluding tissues rich in fats), penetrates into the pleura, peritoneum, lymph, ocular fluid and placenta.

The maximum concentration of ciprofloxacin in the blood serum is noted after 1.5-2 hours, the therapeutic concentration is maintained

for 24 hours after a single oral administration of the drug.

Ciprofloxacin is excreted from the body mainly unchanged and partly in the form of metabolites with urine and bile, in lactating animals – partly with milk.

CIPROVET® tablets, according to the degree of exposure to the body, belong to moderately dangerous substances (hazard class 3 according to GOST 12.1.007-76), in recommended doses do not have a locally irritating effect, do not have embryotoxic and teratogenic properties.

III. Administration procedure

CIPROVET® tablets are prescribed to dogs and cats for therapeutic purposes in acute and chronic diseases of the bacterial etiology of the respiratory organs, gastrointestinal tract, biliary tract, urinary and reproductive system, skin, soft tissues, bones and joints, pathogens of which are sensitive to ciprofloxacin.

Contraindications to use are increased individual sensitivity of the animal to the components of the drug, pronounced disorders of the development of cartilage or bone tissue, lesions of the nervous system, accompanied by convulsions.

When working with CIPROVET® tablets, the general rules of personal hygiene and safety provided for when working with medicines should be observed. Wash your hands with soap and water after handling the drug. Empty drug packaging may not be used for household purposes and must be disposed of with household waste.

People with hypersensitivity to the components of the drug should avoid direct contact with CIPROVET® tablets. In case of accidental contact of the drug with the skin or mucous membranes of the eyes, they must be rinsed with plenty of water. In case of allergic reactions or accidental ingestion of the drug into the human body, it is necessary to immediately contact a medical institution (have the instructions for use or label with you).

It is not allowed to use CIPROVET® tablets to females during pregnancy and lactation, puppies and kittens until the end of the growth period.

The drug is administered to animals individually orally (inside) once a day for 3-5 days in the following doses:

- “CIPROVET® tablets for cats and dogs of small breeds” – 1 tablet per 3 kg of animal weight;
- “CIPROVET® tablets for dogs” – dogs of medium and large breeds – 1 tablet per 10 kg of animal weight.

When using CIPROVET® tablets in accordance with this instruction, side effects and complications in animals are usually not observed. With increased individual sensitivity of the animal to the components of the drug and the appearance of side effects (refusal of feed, vomiting, edema, impaired coordination of movements), the use of CIPROVET® tablets is discontinued and desensitizing therapy is prescribed.

With an overdose of the drug, the animal may experience a decrease in appetite, depression, vomiting. In this case, you should stop using the drug and prescribe antihistamines and symptomatic therapy.

CIPROVET® tablets should not be used simultaneously with bacteriostatic antibiotics (levomycetin, macrolides and tetracyclines), theophiline and nonsteroidal anti-inflammatory drugs, as well as with preparations containing magnesium, aluminum and calcium cations, which, by binding to ciprofloxacin, prevent its adsorption.

The peculiarities of the drug's action during its first use and upon cancellation were not revealed.

Skipping the next dose of the drug should be avoided, as this may lead to a decrease in therapeutic efficacy. In case of skipping one or more doses, the use of the drug is resumed at the same dose and according to the same application scheme.

CIPROVET® tablets are not intended for use by productive animals



Name and address of the production site of the manufacturer of the drug product for veterinary use:
AVZ S-P, Russia, 141305, Moscow region, Sergiev Posad, Tsentralnaya str., 1.

Name, address of the organization authorized by the holder or owner of the registration certificate of the drug to accept claims from the consumer: AVZ S-P, Russia, 141305, Moscow region, Sergiev Posad, Tsentralnaya str., 1.
Phone number of the round-the-clock Hotline: 8-800-700-19-93 (toll-free call from Russia).

Information about the drug is available on the website www.avzvet.ru